Systolic hypertension in Europe (Syst-Eur) trial phase 2: Objectives, protocol, and initial progress

Journal of Human Hypertension

Volumn 13, Issue 2, 1999, Pages 135-145

  Gasowski, J ^b   Staessen, Jan A ^a   Celis, H ^b   Fagard, R H ^b   Thijs, L ^b   Birkenhager W H ^b   Bulpitt, C J ^b   Fletcher, A E ^b   Arabidze, G G ^b   De Leeuw, P ^b   Dollery, C T ^b   Duggan, J ^b   Kawecka Jaszcz, K ^b   Leonetti, G ^b   Nachev, C ^b   Safar, M ^b   Rodico, J L ^b   Rosenfeld, J ^b   Seux, M L ^b   Tuomilehto, J ^b   Webster, J ^b   Yodfat, Y ^b   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NONE

Author keywords

Calcium channel blockade; Dihydropyridine; Elderly; Isolated systolic hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIHYDROPYRIDINE DERIVATIVE; ENALAPRIL; HYDROCHLOROTHIAZIDE; NITRENDIPINE; PLACEBO;

ADULT; AGED; ARTICLE; CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; EUROPE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SITTING; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

EID: 0032991555     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000769     Document Type: Article

References (32)

1. Amery A et al. Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization. Aging Clin Exp Res 1991; 3: 287-302.
2. Goa KL, Sorkin EM Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of hypertension. Drugs 1987; 33: 123-155.
3. Staessen JA et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension [correction published in Lancet 1997, volume 350, 29 November, p 1636]. Lancet 1997; 350: 757-764.
4. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
5. Frohlich ED, Zanchetti A. Antihypertensive therapy: safety and efficacy of drugs and publications. Hypertension 1996; 27: 317-318.
6. Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier Circulation 1995; 92: 1068-1073.
7. McMurray J, Murdoch D. Calcium-antagonist controversy: the long and short of it? Lancet 1997; 349: 585-586.
8. Walker JF, Stampfer MJ. Observational studies of drug safety. Lancet 1997; 348: 489.
9. Staessen JA et al. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension 1998; 32: 410-416.
10. Gong L et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-1245.
11. Liu L, Wang JG, Gong L, Liu G, Staessen JA, for the Systolic Hypertension in China (Syst-China) Collaborative Group: Comparison of active treatment and placebo for older patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823-1829.
12. Pahor M et al. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 695-699.
13. Pahor M et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348: 493-497.
14. Pahor M et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347: 1061-1065.
15. Psaty BM et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-625.
16. Alderman MH, Cohen H, Roqué R, Madhavan S. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349: 594-598.
17. Tatti P et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.
18. Estacio RO et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-652.
19. Alderman M, Madhavan S, Cohen H. Calcium antagonists and cardiovascular events in patients with hypertension and diabetes. Lancet 1998; 351: 216-217.
20. Byington RP, Craven TE, Furberg CD, Pahor M. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet 1998; 350: 1075-1076.
21. Pahor M, Kritchevsky, SB, Zuccala G, Guralnik JM. Diabetes and risk of adverse events with calcium antagonists. Diabetes Care 1998; 21: 193-194.
22. Pahor M, Psaty BM, Furberg CD. Treatment of hypertensive patients with diabetes. Lancet 1998; 351: 689-690.
23. 41st World Medical Assembly: Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull Pan Am Health Organ 1990; 24: 606-609.
24. World Health Organization. International Classification of Diseases. Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. Based on the Recommendations of the Ninth Revision Conference, 1975, and Adopted by the Twenty-Ninth World Health Assembly. Volume 1. Geneva, Switzerland, World Health Organization, 1977.
25. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556.
26. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413-2446.
27. Staessen JA et al. Subgroup and per-protocol analysis of the randomized European trial on isolated systolic hypertension in the elderly. Arch Intern Med 1998; 158: 1681-1691.
28. Jick H et al. Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-528.
29. Tuomilehto J et al. Cardiovascular prognosis in older diabetic and nondiabetic patients treated or untreated for isolated systolic hypertension. N Engl J Med 1998 (submitted for publication).
30. Forette F et al. Is prevention of vascular dementia possible? The Syst-Eur Vascular Dementia Project. Aging Clin Exp Res 1991; 3: 373-382.
31. Seux ML et al. Correlates of cognitive status of old patients with isolated systolic hypertension: the Syst-Eur Vascular Dementia Project. J Hypertens 1998; 16: 963-969.
32. Forette F et al. Prevention of dementia in the double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-1351.